Loading clinical trials...
Loading clinical trials...
Randomized, Double-Blind, Safety and Efficacy Trial With Intravenous Zoledronic Acid for the Treatment of Paget's Disease of Bone Using Risedronate as a Comparator, Including an Extended Observation Period
Conditions
Interventions
zoledronic acid
placebo to zoledronic acid
+3 more
Locations
41
United States
Novartis Investigative site
Tucson, Arizona, United States
Novartis Investigative Site
Colorado Springs, Colorado, United States
Novartis Investigative Site
Indianapolis, Indiana, United States
Novartis Investigative Site
New Orleans, Louisiana, United States
Novartis Investigative Site
Boston, Massachusetts, United States
Novartis Investigative Site
Syracuse, New York, United States
Start Date
April 1, 2002
Primary Completion Date
December 1, 2003
Completion Date
April 1, 2011
Last Updated
June 4, 2012
NCT02802384
NCT00051636
NCT00747994
NCT00306046
Lead Sponsor
Novartis Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions